Please assess the completion status of the following clinical trial:

Trial Title: Compare Ticagrelor vs Clopidogrel on the Reduction of Arterial Stiffness and Wave Reflectionsin Patients With CAD.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Provision of informed consent prior to any study specific procedures.~2. Male and female subjects \> 18 and \< 79 years of age.~3. Indication for elective coronary angiography (angina, positive stress test/SPECT/stress echo) with or without PCI for inclusion in the 'acute' study period, and indication for either ad hoc or elective PCI for inclusion in the 'chronic' study period.~Exclusion Criteria:~1. Who had ACS within 12 months of screening.~2. Previous stent implantation with dual antiplatelet therapy within 12 months of screening.~3. Subjects being treated with anti-platelet medications other than aspirin prior to diagnostic catheterization including glycoprotein IIb/IIIa inhibitors.~4. Subjects with NYHA class III or IV heart failure or known left ventricular ejection fraction \< 30%.~5. Subjects with hemodynamic or electrical instability (including shock).~6. History of gastrointestinal bleeding, genitourinary bleeding or other site abnormal bleeding within the previous 6 months.~7. Other bleeding diathesis, or considered by Investigator to be at high risk for bleeding.~8. Any previous history of ischemic or hemorrhagic stroke, intracranial hemorrhage or disease (neoplasm, arteriovenous malformation, aneurysm).~9. International Normalized Ratio (INR) known to be \>1.5 within 1 week of study entry.~10. Poorly controlled blood pressure (\>160/100 mmHg).~11. Known platelet count of \<100,000/mm3 within 1 week of study entry.~12. Known anemia (hemoglobin \[Hb\] \<10 gr/dL) within 1 week of study entry.~13. Subjects receiving daily treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) or cyclooxygenase-2 (COX-2) inhibitors that cannot be discontinued for the duration of the study.~14. Severe kidney disease (GFR\<30 ml/min/1.73m2).~15. Hepatic insufficiency defined as liver cirrhosis, AST/ALT/Alkaline Phosphatase greater than 3 times the upper limit of normal or hyperbilirubinemia defined as peak total serum bilirubin greater than 2 times the upper limit of normal (ULN).~16. Any indication (atrial fibrillation, mitral stenosis or prosthetic heart valve, pulmonary embolism (PE), deep vein thrombosis (DVT)) for anticoagulation treatment during study period.~17. Asthma or chronic obstructive pulmonary disease requiring brochodilating agents.~18. Concomitant use of potent Cytochrome P450 3A4 (CYP3A4) inhibitors (atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin and voriconazole) or inducers (carbamazepine, dexamethasone, phenobarbital, phenytoin, rifampin, and rifapentine).~19. Concomitant use of drugs that are metabolized through CYP2C19 (omeprazole and esomeprazole, fluvoxamine, fluoxetine, moclobemide, voriconazole, fluconazole, ticlopidine, ciprofloxacin, cimetidine, carbamazepine, oxcarbazepine and chloramphenicol).~20. History of uric acid nephropathy and high levels of uric acid within 1 week of study entry.~21. Increased risk of bradycardic events (e.g. known sick sinus syndrome or third degree AV block or previous documented syncope suspected to be due to bradycardia unless treated with a pacemaker).~22. Known neoplastic or autoimmune disease or any concomitant medical illness that in the opinion of the Investigator may interfere with or prevent completion in this study.~23. Contraindication to clopidogrel, ASA, or ticagrelor.~24. A history of alcohol and/or substance abuse that could interfere with conduct of the trial.~25. Pregnancy or lactation (for premenopausal women 2 methods of reliable contraception, one of which must be barrier method, are required).~26. Treatment with other investigational agents (including placebo) or devices within 30 days prior to randomization or planned use of investigational agents or devices prior to the Day 30 visit.~27. Life expectancy less than 1 year.~28. Indication for major surgery (e.g. cancer treatment, carotid surgery, cerebral surgery, major vascular surgery).~29. High likelihood of being unavailable for the Day 30 follow up.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Clopidogrel (Type: ACTIVE_COMPARATOR): Loading dose 600 mg .Mainatinance dose 75 mg QD
- Ticagrelor (Type: EXPERIMENTAL): Loading dose 180 mg . Maintenance 90 mg BID

Based on this trial design, predict the completion outcome and termination type (if applicable).